On June 30, 2025, Oragenics Inc. filed an 8-K announcing a public offering of 660,000 shares of Series H Convertible Preferred Stock, which can convert into up to 9,570,000 shares of common stock, raising approximately $16.5 million for ongoing research, loan repayment, and general corporate purposes.